Neuroanatomical changes in Parkinson’s disease in relation to cognition: An update

K. G. Prakash¹, B. M. Bannur², Madhavrao D. Chavan³, K. Saniya⁴, Kumar Sai Sailesh⁵, Archana Rajagopalan⁶

¹Departments of Anatomy and Pharmacology, Azeezia Institute of Medical Sciences and Research Centre, Kollam, ²Department of Anatomy, Shri B. M. Patil Medical College, Hospital and Research Centre (B. L. D. E. University), Bijapur, Karnataka, ³Department of Physiology, Little Flower Institute of Medical Sciences and Research, Angamaly, Kerala, ⁴Department of Physiology, Saveetha Medical College, Saveetha University, Chennai, Tamil Nadu, India

Abstract

The pathophysiological changes underlying impairment of cognition in Parkinson’s disease (PD) are complex and not fully understood till date. Hence, understanding the structural changes responsible for cognitive decline in PD is essential for early diagnosis and to offer effective treatment. In this review, we discuss the neuroanatomical changes in major brain structures responsible for cognition in PD. We have included the key findings of various studies to provide up-to-date information for better understanding of pathophysiology of PD, which will help researchers and clinicians in planning and developing new treatment methods for the benefit of PD patients.

Key words: Cognition, neuroanatomical changes, nonmotor features, Parkinson’s disease

INTRODUCTION

Parkinson’s disease (PD) is characterized by slowness of movement, rigidity, tremor, postural instability, and often cognitive impairments.[1] Although motor features are more prominent in PD, nonmotor features also have been diagnosed in PD patients.[2] Acetylcholine, norepinephrine, and serotonin may have a role in nonmotor features of PD. Features include cognitive impairment, psychological, autonomic, and sleep disorders which decrease the quality of life further.[3,4] The pathophysiological changes underlying impairment of cognition in PD are complex and not fully understood till date.[5] Hence, understanding the structural changes responsible for cognitive decline in PD is essential for early diagnosis and to offer effective treatment.[6-8] In this review, we discuss the neuroanatomical changes in major brain structures responsible for cognition in PD.

Address for correspondence:
Dr. K. G. Prakash,
Department of Anatomy, Azeezia Institute of Medical Sciences and Research Centre, Meeyannoor, Kollam, Kerala, India.
E-mail: drprakashkg@gmail.com

Changes in Basal Ganglia in Parkinson’s Disease

Since changes in the morphology of basal ganglia are noticed in bipolar and unipolar disorders also, it is essential to understand the changes in basal ganglia in PD for reliable diagnosis. Basal ganglia process the signals from the cortex for accurate execution of voluntary movements.[9] Basal ganglia play a key role in cognitive functions,[10] and lesion of basal ganglia causes impairment in cognitive functions.[11] In fact, basal ganglia are the most affected brain area in PD.[12] It was reported that there were two subtypes of PD and each type will affect basal ganglia in a different fashion. The subtypes include heterogeneous clinical phenotypes such as tremor dominant (TD) and postural instability/gait difficulty (PIGD).[13] PD patients had reduced fractional anisotropy within the substantia nigra and increased mean and radial diffusivity within the substantia nigra and globus pallidus. However, microstructural changes within the substantia nigra are severely affected in PIGD patients compared to TD.[14]
Reduction of the neuromelanin pigmentation, neuronal loss, and Lewy bodies are observed in the substantia nigra. In PD patients, basal ganglia undergoatrophy, which depends on severity and duration of the disease. In PD patients, loss of attenuation and length of the dendritic spines of medium-sized spiny neurons located in the striatum has been reported. Reduction in the volumes of the caudate nucleus and thalamus and white matter is observed in PD, which may be an early sign of disease progression.

**CHANGES IN CEREBELLUM IN PARKINSON’S DISEASE**

Increased activity of the cerebellum was observed during cognitive tasks. The cerebellum has reciprocal connections with basal ganglia, and Parkinson’s-related morphological changes were observed in animal models and humans. These changes include significant contraction in the left cerebellum, decrease in the gray matter volume in the right quadrangular lobe. These changes may be induced by degeneration of dopaminergic neurons as the cerebellum receives dopaminergic projections from basal ganglia, and dopaminergic receptors were present in the cerebellum.

**CHANGES IN BRAIN VOLUME IN PARKINSON’S DISEASE**

Strong correlation exists between brain size and cognitive functions. In PD patients, atrophy of the brain was observed in many cortical and subcortical areas, which contributes in decrease in the volume of the brain. Interestingly, it was reported that volume of the frontal lobe, temporoparietal junction, parietal lobe, insula, anterior cingulate cortex, basal ganglia, and thalamus increased in PD patients. Prefrontal lobe plays a crucial role in cognitive functions and in PD patients; loss of gray matter has been reported.

**CHANGES IN THALAMUS IN PARKINSON’S DISEASE**

Thalamic lesions are found to impair cognitive functions such as language, memory, and attention. Thalamic stimulation was effective in enhancement of cognition through activation of neocortex and hippocampus and modulating gene expression. Approximately 30%–40% loss was reported in the thalamus in PD. It was reported that volume of the thalamus decreases in PD. In contrast, it was reported that thalamic shape but not volume changes in PD. As specific nuclei of the thalamus are involved in PD, atrophy of the caudal intralaminar nucleus and hypertrophy of rest of the nucleus result in altered shape of the thalamus. Further, changes in white matter of the mediodorsal thalamus lead to depression in most of the PD patients. Significant reduction in fractional anisotropy was reported in anterior nucleus, dorsomedial nucleus, and ventral anterior nucleus of the thalamus.

**CHANGES IN HYPOTHALAMUS IN PARKINSON’S DISEASE**

Role of the hypothalamus in cognitive functions is well documented. Atrophy of gray matter was observed in Parkinson’s patients with dementia. Dopamine dysfunction in the limbic system leads to change in the creativity and emotional dysfunction in PD patients. In amygdala, accessory cortical and central nuclei are affected more by PD, and cortical, accessory basal, and granular nuclei are least affected areas. Posterior cingulum is the important structure in the papez circuit which is involved in processing of episodic memory. It was reported that neuronal loss, gliosis, or demyelination in the white matter and metabolic changes occurs in the cingulum of PD patients. Change in the spontaneous resting-state neural activity is reported in prefrontal cortex, which was considered as a factor for cognitive decline in PD. Further, regional atrophy in the hippocampus contributes to impaired verbal learning memory and visuospatial processing.

**CHANGES IN LOCUS COERULEUS IN PARKINSON’S DISEASE**

Loss of noradrenergic neuronal and Lewy bodies formation was much higher in locus coeruleus (LC) than dopaminergic neuronal loss in PD patients. Resting tremors of PD are due to neuronal loss of LC. About 35% of PD patients were depressed, and loss of noradrenergic pathways underlies the pathophysiology of depression in PD. The pathological changes in LC of PD patients are peculiar and can be differentiated from changes that occur in other
neurodegenerative diseases such as schizophrenia.\textsuperscript{[50]} It was reported that simultaneous lesions of dopaminergic system, and LC causes metabolic dysfunction in the cerebral cortex and impairs cognitive functions in PD.\textsuperscript{[51]}

**CHANGES IN GLIAL CELLS IN PARKINSON’S DISEASE**

All glial cells can influence the cognitive functions.\textsuperscript{[52]} Structural changes occur in astrocytes in response to physiological and pathological conditions may influence the neurons through nonsynaptic communication with neurons.\textsuperscript{[53–55]} Altered neuroglial interaction may be the underlying cause for many neurological diseases including PD.\textsuperscript{[56]} Glial response in PD offers both beneficial and hazardous effects.\textsuperscript{[57]}

**CONCLUSION**

In this review, we have presented the neuroanatomical changes of major brain structures related to cognition in PD. We have included the key findings of various studies to provide up-to-date information for better understanding of pathophysiology of PD, which helps researchers and clinicians in planning and developing new treatment methods for the benefit of PD patients.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Eriksen JL, Wszolek Z, Petrucelli L. Molecular pathogenesis of Parkinson disease. Arch Neurol 2005;62:353-7.
2. Hughes TA, Ross HF, Mindham RH, Spokes EG. Mortality in Parkinson’s disease and its association with dementia and depression. Acta Neurol Scand 2004;110:118-23.
3. Levy G, Tang MX, Louis ED, Côté LJ, Alfaro B, Mejia H, et al. The association of incident dementia with mortality in PD. Neurology 2002;59:1708-13.
4. Goldman JG, Litvan I. Mild cognitive impairment in Parkinson’s disease. Minerva Med 2011;102:441-59.
5. Yarnall AJ, Rochester L, Burn DJ. Mild cognitive impairment in Parkinson’s disease. Age Ageing 2013;42:567-76.
6. Aasland D, Bronnick K, Williams-Gray C, Weintraub D, Marder K, Kulisevsky J, et al. Mild cognitive impairment in Parkinson disease: A multicenter pooled analysis. Neurology 2010;75:1062-9.
7. Doméllöf ME, Elgh E, Forsgren L. The relation between cognition and motor dysfunction in drug-naive newly diagnosed patients with Parkinson’s disease. Mov Disord 2011;26:2183-9.
8. Meireles J, Massano J. Cognitive impairment and dementia in Parkinson’s disease: Clinical features, diagnosis, and management. Front Neurol 2012;3:88.
9. Blandini F, Nappi G, Tassorelli C, Martignoni E. Functional changes of the basal ganglia circuitry in Parkinson’s disease. Prog Neurobiol 2000;62:63-88.
10. Brown LL, Schneider JS, Lidsky TJ. Sensory and cognitive functions of the basal ganglia. Curr Opin Neurol 1997;7:157-63.
11. Leisman G, Melillo R, Carrick FR. Clinical motor and cognitive neurobehavioral relationships in the basal ganglia. In: Franz E, editor. Basal Ganglia. Rijeka: InTech; 2013. p. 1-30.
12. Obeso JA, Rodriguez-Oroz MC, Benitez-Temino B, Blesa FJ, Guridi J, Marin C, et al. Functional organization of the basal ganglia: Therapeutic implications for Parkinson’s disease. Mov Disord 2008;23 Suppl 3:5548-59.
13. Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L, et al. Variable expression of Parkinson’s disease: A base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 1990;40:1529-34.
14. Nagae LM, Honce JM, Tanabe J, Sillau SH, Berman BD. Microstructural changes within the basal ganglia differ between Parkinson disease subtypes. Front Neuroanat 2016;10:17.
15. Dickson DV. Neuropathology of movement disorders. In: Tolosa E, Jankovic JJ, editors. Parkinson’s Disease and Movement Disorders. Hagerstown, MD: Lippincott Williams & Wilkins; 2007. p. 271-83.
16. Reetz K, Gaser C, Klein C, Hagenah J, Büchel C, Gottschalk S, et al. Structural findings in the basal ganglia in genetically determined and idiopathic Parkinson’s disease. Mov Disord 2009;24:99-103.
17. Stephens B, Mueller AJ, Shering AF, Hooi SH, Taggart P, Arbuthnott GW, et al. Evidence of a breakdowm of corticostriatal connections in Parkinson’s disease. Neuroscience 2005;132:741-54.
18. Lee SH, Kim SS, Tae WS, Lee SY, Choi JW, Koh SB, et al. Regional volume analysis of the Parkinson disease brain in early disease stage: Gray matter, white matter, striatum, and thalamus. AJNR Am J Neuroradiol 2011;32:682-7.
19. Stoodley CJ. The cerebellum and cognition: Evidence from functional imaging studies. Cerebellum 2012;11:352-65.
20. Rolland AS, Herrero MT, Garcia-Martinez V, Ruberg M, Hirsch EC, François C. Metabolic activity of cerebellar and basal ganglia-thalamic neurons is reduced in Parkinsonism. Brain 2007;130(Pt 1):265-75.
21. Borghammer P, Østergaard K, Cumming P, Gjedde A, Rodell A, Hall N, et al. A deformation-based morphometry study of patients with early-stage Parkinson’s disease. Eur J Neurol 2010;17:514-20.
22. Wu T, Hallett M. The cerebellum in Parkinson’s disease. Brain 2013;136(3 Pt 5):696-709.
23. Giompres P, Delis F. Dopamine transporters in the cerebellum of mutant mice. Cerebellum 2005;4:105-11.
24. Rushton JP, Ankney CD. Whole brain size and general mental ability: A review. Int J Neurosci 2009;119:691-731.
25. Watts RL, Standaertt DG, Obeso JA, editors. Movement Disorders. 3rd ed. New York: McGraw Hill; 2011.
26. Cerasa A, Messina D, Pugliese P, Morelli M, Lanza P, Salsone M, et al. Increased prefrontal volume in PD with levodopa-induced dyskinesias: A voxel-based morphometry study. Mov Disord 2011;26:807-12.
27. Siddiqui SV, Chatterjee U, Kumar D, Siddiqui A, Goyal N. Neuropsychology of prefrontal cortex. Indian J Psychiatry 2008;50:202-8.
28. Biundo R, Formento-Dojot P, Facchini S, Vallelunga A, Ghezzo L, Cerasa A, et al. Brain volume changes in Parkinson’s disease and their relationship with cognitive and behavioural abnormalities. J Neurol Sci 2011;310:64-9.
29. Aglioti S. The role of the thalamus and basal ganglia in human cognition. J Neurolinguistics 1997;10:255-69.
30. Shivalkar P, Seth M, Schiiff ND, Herrera DG. Cognitive enhancement with central thalamic electrical stimulation. Proc Natl Acad Sci U S A 2006;103:17007-12.
31. Halliday GM. Thalamic changes in Parkinson’s disease. Parkinsonism Relat Disord 2009;15 Suppl 3:S152-5.
32. McKeown MJ, Uthama A, Abugharbieh R, Palmer S, Lewis M, Huang X. Shape (but not volume) changes in the thalamus in Parkinson disease. BMC Neurol 2008;8:8.
33. Li W, Liu J, Skidmore F, Liu Y, Tian J, Li K. White matter microstructure changes in the thalamus in Parkinson disease with depression: A diffusion tensor MR imaging study. AJNR Am J Neuroradiol 2010;31:1861-6.
34. Planetta PJ, Schulze ET, Geary EK, Corcos DM, Goldman JG, Little DM, et al. Thalamic projection fiber integrity in de novo Parkinson disease. AJNR Am J Neuroradiol 2013;34:74-9.
35. Zimmerman D. Thinking with your hypothalamus. Philos Phenomenol Res 2001;63:321-41.
36. Langston JW, Forno LS. The hypothalamus in Parkinson disease. Ann Neurol 1978;3:129-33.
37. Politis M, Piccini P, Pavese N, Koh SB, Brooks DJ. Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson’s disease: An in vivo 11C-raclopride PET study. Exp Neurol 2008;214:112-6.
38. Breen DP, Nombela C, Vuono R, Jones PS, Fisher K, Burn DJ, et al. Hypothalamic volume loss is associated with reduced melatonin output in Parkinson’s disease. Mov Disord 2016;31:1062-6.
39. Sandyk R, Iacono RP, Bamford CR. The hypothalamus in Parkinson disease. Ital J Neurol Sci 1987;8:227-34.
40. Rajmohan V, Mohandas E. The limbic system. Indian J Psychiatry 2007;49:132-9.
41. Xia J, Miu J, Ding H, Wang X, Chen H, Wang J, et al. Changes of brain gray matter structure in Parkinson’s disease patients with dementia. Neural Regen Res 2013;8:1276-85.
42. Kulisevsky J, Pagonabarraga J, Martinez-Corral M. Changes in artistic style and behaviour in Parkinson’s disease: Dopamine and creativity. J Neurol 2009;256:816-9.
43. Braak H, Braak E, Yilmazer D, de Vos RA, Jansen EN, Bohl J, et al. Amygdala pathology in Parkinson’s disease. Acta Neuropathol 1994;88:493-500.
44. Kamagata K, Motoi Y, Abe O, Shimojo K, Hori M, Nakanishi A, et al. White matter alteration of the cingulum in Parkinson disease with and without dementia: Evaluation by diffusion tensor tract-specific analysis. AJNR Am J Neuroradiol 2012;33:890-5.
45. Camicioli RM, Korzan JR, Foster SL, Fisher NJ, Emery DJ, Bastos AC, et al. Posterior cingulate metabolic changes occur in Parkinson’s disease patients without dementia. Neurosci Lett 2004;354:177-80.
46. De-Zhi K, Fu-Xiang C, Fu-Yong C, Ying L, Gang W, Liang-Hong Y, et al. Altered regional homogeneity of prefrontal cortex in Parkinson’s disease with mild cognitive impairment. Chin Neurosurg J 2016;2:1-7.
47. Duncan GW, Firbank MJ, O’Brien JT, Burn DJ. Magnetic resonance imaging: a biomarker for cognitive impairment in Parkinson’s disease? Mov Disord 2013;28:425-38.
48. Isaias IU, Marzegan A, Pizzoli G, Marotta G, Canesi M, Biella GE, et al. A role for locus coeruleus in Parkinson tremor. Front Hum Neurosci 2012;5:179.
49. Bertrand E, Lechowicz W, Szpak GM, Dymecki J. Qualitative and quantitative analysis of locus coeruleus neurons in Parkinson’s disease. Folia Neuropathol 1997;35:80-6.
50. Ferreira D, Guerra A. Depression and Parkinson’s disease: Role of the locus coeruleus. Eur Psychiatry 2015;30:641.
51. Schwartz W, Sharp FR, Gunn RH, Evarts EV. Lesions of ascending dopaminergic pathways decrease forebrain glucose uptake. Nature 1976;261:155-7.
52. Fields RD, Araque A, Johansen-Berg H, Soo-Siang L, Lynch G, Klaus-Armin N, et al. Glial biology in learning and cognition. Neuroscientist 2014;20:426-31.
53. Theodosis DT, MacVicar B. Neurone-glia interactions in the hypothalamus and pituitary. Trends Neurosci 1996;19:363-7.
54. Theodosis DT, Poulain DA, Oliet SH. Activity-dependent structural and functional plasticity of astrocyte-neuron interactions. Physiol Rev 2008;88:983-1008.
55. Villalba RM, Smith Y. Neuroglial plasticity at striatal glutamatergic synapses in Parkinson’s disease. Front Syst Neurosci 2011;5:68.
56. Voronkov DN, Khudoerkov RM, Dovedova EL. Changes in neuroglial interactions in nigrostriatal brain structures on modeling of dopamine system dysfunction. Neurosci Behav Physiol 2014;44:1073-7.
57. Vicl M, Jackson-Lewis V, Guégan C, Wu DC, Teismann P, Choi DK, et al. The role of glial cells in Parkinson’s disease. Curr Opin Neurol 2001;14:483-9.